Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 358

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 358
---
 the
Consolidated Financial Statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the Consolidated Financial Statements. We believe that our audits provide
a reasonable basis for our opinion.

Critical Audit Matters

| F-21 |

The critical audit matters communicated below
are matters arising from the current period audit of the Consolidated Financial Statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the Consolidated Financial Statements and
(2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter
in any way our opinion on the Consolidated Financial Statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

We have identified one
critical audit matter, being the going concern basis of preparation. The nature of the critical audit matter, together with our conclusion,
is set out above in the going concern uncertaintyparagraph. Given the circumstances described, the Directors were required
to exercise significant judgement in making their assessment as to whether it is appropriate to prepare the Consolidated Financial Statements
on a going concern basis and in preparing their related explanatory disclosures. As a result of the requirement for the Directors to exercise
significant judgment, much of which is qualitative in nature, together with the pervasive impact of the going concern basis of preparation
and the importance of the related explanatory disclosures in providing context for the Consolidated Financial Statements, we have concluded
that the going concern basis of preparation is a critical audit matter.

Our evaluation of the Directors’ assessment
of the appropriateness of the going concern basis of preparation of these consolidated financial statements included, but was not limited
to:

| · | Undertaking an initial assessment at the planning                                                                                 
 stage of the audit to identify events or conditions that may cast significant doubt on the Group’s ability to continue as a going 
 concern;                                                                                                                          |

| · | Obtaining an understanding of the relevant controls relating to the Directors’ 
 going concern assessment;                                                      |

| · | Reviewing the Directors’ formal going concern                                   
 assessment, including the supporting cash flow projections to 31 December 2026; |

| · | Evaluating the key assumptions used and judgements                          
 applied by the Directors in forming their conclusions on going concern; and |

| ·